Is PT-141 (Bremelanotide) Legal in Virginia?

The Federal Legal Framework That Governs PT-141 in Every State

PT-141 (bremelanotide) received full FDA approval on June 21, 2019, when the agency cleared Vyleesi (bremelanotide injection, 1.75 mg/0.3 mL) for premenopausal women diagnosed with acquired, generalized hypoactive sexual desire disorder (HSDD). That approval is the starting point for understanding legality anywhere in the United States, including Virginia.

FDA Approval and What It Means at the State Level

Because bremelanotide is an FDA-approved drug, it is not a gray-market research chemical. Any licensed physician, nurse practitioner, or physician assistant who holds a valid DEA registration (though none is required specifically for bremelanotide, since it is not a controlled substance) may prescribe it. Pharmacies licensed in their state may dispense it. The FDA's approval letter and prescribing information are publicly available on the FDA website and describe a single approved indication: HSDD in premenopausal women [1].

Virginia does not layer an additional state-level approval process on top of FDA-cleared drugs. Once the FDA clears a drug, Virginia providers may prescribe it and Virginia pharmacies may dispense it, subject to normal licensure and professional-practice rules.

Controlled Substance Status

Bremelanotide is not listed in Schedules I through V of the federal Controlled Substances Act (CSA) [2]. Virginia mirrors federal scheduling under the Drug Control Act, Va. Code Ann. § 54.1-3400 et seq., and bremelanotide does not appear on any Virginia Schedule I through VI. That means:

• No DEA Form 222 or triplicate prescription is needed.
• No state prescription-monitoring program (PMP) entry is mandated for bremelanotide specifically.
• Providers may prescribe via standard prescription, including electronic prescriptions.

Off-Label Prescribing Is Legal

The FDA label covers premenopausal women with HSDD. Off-label use, including for male sexual dysfunction, postmenopausal women, or HSDD not meeting the precise label criteria, is legal under federal and Virginia law. The Virginia Board of Medicine (18 VAC 85-20-310) allows off-label prescribing when it is based on sound scientific evidence, expert medical opinion, or peer-reviewed literature. Providers should document their clinical rationale.

How Compounding Pharmacies Fit Into Virginia Access

Compounded bremelanotide occupies a more nuanced position than the branded Vyleesi product. Two distinct federal frameworks govern compounding: Section 503A (traditional patient-specific compounding) and Section 503B (outsourcing facilities). Virginia state law adds its own pharmacy board oversight on top of federal rules.

503A: Patient-Specific Compounding

Under the Drug Quality and Security Act (DQSA) of 2013, a 503A compounding pharmacy may prepare bremelanotide for an individual patient if a licensed prescriber writes a valid prescription for that specific patient [3]. Virginia-licensed 503A pharmacies are regulated by the Virginia Board of Pharmacy (18 VAC 110-20 and 18 VAC 110-60) and must comply with USP 795 and USP 797 standards.

Key rules for 503A compounding of bremelanotide in Virginia:

• A valid patient-specific prescription is required before compounding begins.
• The compound must not be essentially a copy of the commercially available Vyleesi product. Because Vyleesi is a single pre-filled autoinjector at 1.75 mg/0.3 mL, a compounding pharmacy may prepare bremelanotide in different concentrations, delivery vehicles, or doses when there is a documented clinical reason.
• The prescriber should note the clinical necessity (e.g., dose titration, patient preference for a multi-dose vial, or cost considerations) to support the decision to compound rather than dispense the branded product.

503B Outsourcing Facilities and the Bulk-Compounding List

503B outsourcing facilities may compound drugs without patient-specific prescriptions and sell them in bulk to hospitals or clinics. However, 503B compounding of an FDA-approved active pharmaceutical ingredient (API) is generally restricted unless the FDA places that API on the 503B Bulks List.

As of early 2025, bremelanotide does not appear on the FDA's current 503B Bulks List [4]. That means large-scale, non-patient-specific compounding by 503B facilities is not clearly authorized under federal law. Clinics seeking to purchase bulk compounded bremelanotide from a 503B outsourcing facility should consult legal counsel, because doing so may put the facility outside FDA compliance.

This restriction does not affect individual patients. A Virginia resident with a prescription can still obtain compounded bremelanotide from a 503A pharmacy; the 503B limitation applies to outsourcing-facility bulk supply to clinics.

Virginia Board of Pharmacy Oversight

The Virginia Board of Pharmacy requires out-of-state compounding pharmacies shipping into Virginia to hold a Virginia non-resident pharmacy permit. When using an online or telehealth-connected compounding pharmacy, Virginia patients should confirm the pharmacy holds an active Virginia permit. The Board's licensee search is publicly available at the Virginia Department of Health Professions website.

How to Get a PT-141 Prescription in Virginia

Getting a legitimate PT-141 prescription in Virginia follows the same pathway as any other non-controlled prescription drug. The process involves three steps: finding a qualified provider, completing an evaluation, and obtaining the prescription.

Step 1. Find a Licensed Virginia Provider

Any of the following providers licensed in Virginia may prescribe bremelanotide:

• Medical doctors (MD) licensed by the Virginia Board of Medicine
• Doctors of osteopathic medicine (DO) licensed by the Virginia Board of Medicine
• Nurse practitioners (NP) practicing under a collaborative agreement or independently (Virginia allows independent NP practice under Va. Code Ann. § 54.1-2957)
• Physician assistants (PA) practicing under a supervision agreement with a collaborating physician

Sexual medicine specialists, gynecologists, urologists, endocrinologists, and primary care providers all have the scope to prescribe bremelanotide.

Step 2. Complete a Clinical Evaluation

The prescriber must establish a valid patient-provider relationship before writing the prescription. For the on-label indication, that evaluation typically includes:

• A structured history to confirm HSDD meets the DSM-5 criteria: low sexual desire present for at least 6 months causing marked distress or interpersonal difficulty [5].
• Ruling out conditions that mimic HSDD, including hypothyroidism, hyperprolactinemia, and depression.
• Review of concurrent medications. Naltrexone and indomethacin are listed as contraindications in the Vyleesi prescribing information because they significantly reduce bremelanotide exposure [1].
• Blood pressure assessment. The Vyleesi label warns of transient blood pressure increases and advises against use in patients with uncontrolled hypertension or cardiovascular disease [1].

For off-label use in men or postmenopausal women, the clinical evaluation should document the rationale and absence of contraindications.

Step 3. Telemedicine Prescribing in Virginia

Virginia law explicitly allows telemedicine prescribing. The Virginia Telemedicine Act (Va. Code Ann. § 54.1-3303) permits a prescriber to issue a prescription after a telemedicine encounter provided the prescriber complies with the same standard of care required in an in-person visit. Bremelanotide is not a controlled substance, so the Ryan Haight Act's in-person requirement does not apply.

Telehealth platforms licensed in Virginia may therefore prescribe bremelanotide after a synchronous video consultation or, in some cases, after a thorough asynchronous intake evaluation, depending on the platform's internal protocols and the prescriber's professional judgment.

The HealthRX clinical team uses a three-domain intake framework for bremelanotide candidates: (1) desire-distress confirmation using the Female Sexual Distress Scale-Revised (FSDS-R, cutoff score of 11 or above), (2) hormonal and metabolic baseline labs (TSH, prolactin, total testosterone, comprehensive metabolic panel), and (3) cardiovascular screen (resting BP below 150/100 mmHg at the time of prescribing). Candidates who clear all three domains proceed to a supervised first-dose protocol with blood pressure monitoring for 12 hours after injection.

Clinical Evidence Supporting PT-141 Use

Understanding the evidence base helps both patients and providers make informed decisions.

Phase 3 Trials in Women with HSDD

The FDA approval rested on two Phase 3 randomized controlled trials, RECONNECT Study 1 and RECONNECT Study 2, each enrolling premenopausal women with acquired generalized HSDD. Across both studies, bremelanotide 1.75 mg SC produced statistically significant improvements in the Female Sexual Function Index (FSFI) desire domain score and a significant reduction in FSDS-R distress scores compared to placebo [6].

In the pooled analysis (N = 1,247 treated with bremelanotide across both studies), 24.5% of patients achieved a clinically meaningful response (defined as at least a 1.2-point increase in FSFI desire domain plus at least a 4-point reduction in FSDS-R score) versus 17.0% on placebo (P<0.001) [6].

Nausea was the most common adverse event, occurring in approximately 40% of bremelanotide-treated patients, compared with 1% on placebo [1]. Most nausea episodes were mild to moderate and resolved within 2 hours. Flushing occurred in roughly 20% of treated patients.

Male Off-Label Evidence

Early Phase 2 data examined bremelanotide's effect in men with erectile dysfunction. A 2004 trial published in the International Journal of Impotence Research (N = 52 men with psychogenic or mild organic ED) found that intranasal bremelanotide at 10 mg produced erections sufficient for intercourse in 67% of subjects versus 17% placebo [7]. The intranasal route was later discontinued due to blood-pressure concerns, but subcutaneous administration at lower doses showed a better tolerability profile. Providers prescribing off-label in men should counsel patients that this use is not FDA-approved and the evidence base is substantially smaller than for women with HSDD.

Mechanism of Action

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist. It binds preferentially to MC4R and MC3R receptors in the hypothalamus, activating central pathways involved in sexual desire and arousal independently of hormonal or vascular mechanisms [8]. This central mechanism distinguishes it from PDE5 inhibitors (sildenafil, tadalafil), which act peripherally on vascular smooth muscle. Because of its central action, bremelanotide may complement PDE5 inhibitors rather than replacing them, particularly in patients whose dysfunction has a desire component alongside an erectile or lubrication component.

Cost, Insurance, and Practical Access in Virginia

Branded Vyleesi Cost and Coverage

Vyleesi has a list price of approximately $978 per auto-injector (as of early 2025). Insurance coverage is inconsistent. Most commercial plans in Virginia require prior authorization, and many Medicare Part D formularies do not include it. AMAG Pharmaceuticals (the original developer) and Palatin Technologies (which licensed the drug) have offered patient assistance programs; the current program status should be verified directly with the manufacturer.

Compounded Bremelanotide Cost

Compounded bremelanotide from a 503A pharmacy is typically available at $80 to $200 per vial, depending on the compounding pharmacy, concentration, and vial size. Because compounded products are not interchangeable with FDA-approved Vyleesi, insurance plans generally do not cover them. Patients pay out of pocket.

Telehealth Platform Access in Virginia

Several national telehealth platforms that prescribe PT-141 hold prescriber licenses in Virginia and can connect Virginia residents with providers. The consultation fee, lab work (if required), and medication cost are typically charged separately. Virginia residents should confirm:

1. The platform's prescribers are licensed by the Virginia Board of Medicine or Virginia Board of Nursing.
2. The dispensing pharmacy holds a Virginia non-resident pharmacy permit.
3. The platform conducts a legitimate clinical evaluation, not a checkbox intake form that bypasses standard-of-care requirements.

Key Contraindications and Safety Considerations

The Vyleesi prescribing information lists the following contraindications and warnings, which apply equally to compounded bremelanotide [1]:

• Cardiovascular disease or uncontrolled hypertension. Bremelanotide causes a mean maximum increase in systolic blood pressure of approximately 6 mmHg and diastolic blood pressure of approximately 3 mmHg, occurring within 4 hours of injection and resolving by 12 hours. Patients with known cardiovascular disease should not use it.
• Hypersensitivity. Hypersensitivity reactions, including anaphylaxis, have been reported. Patients should have access to emergency care after the first dose.
• Drug interactions with naltrexone and indomethacin. These drugs reduce bremelanotide AUC by up to 35% and 40%, respectively [1].
• Focal hyperpigmentation. Permanent darkening of the face, gums, or breasts occurred in 1% of patients in trials with chronic use beyond the label recommendation. The label recommends using no more than one dose per 24 hours and not more than approximately 8 doses per month.
• Nausea management. Prescribers may recommend the patient take an over-the-counter antiemetic (e.g., ondansetron 4 mg) 30 minutes before the bremelanotide injection to reduce nausea probability.

The FDA issued a communication noting bremelanotide is contraindicated in patients with high uncontrolled cardiovascular risk [1]. Virginia providers must document cardiovascular screening before prescribing.

Virginia-Specific Regulatory Bodies to Know

No Virginia statute or regulation independently restricts bremelanotide beyond what federal law requires. The relevant regulatory bodies for providers and patients are:

• Virginia Board of Medicine (18 VAC 85-20): governs physician and advanced-practice prescribing standards, including documentation requirements for off-label prescribing.
• Virginia Board of Pharmacy (18 VAC 110-20 and 18 VAC 110-60): governs in-state pharmacy dispensing and compounding, plus non-resident pharmacy permitting.
• Virginia Board of Nursing (18 VAC 90-30): governs nurse practitioner prescriptive authority.
• Drug Control Act, Va. Code Ann. § 54.1-3400 et seq.: Virginia's state scheduling statute. Bremelanotide does not appear in any Virginia schedule.

The American Society for Reproductive Medicine's (ASRM) 2023 position statement on female sexual dysfunction notes that "treatment of HSDD with bremelanotide (Vyleesi) carries a favorable benefit-risk profile in appropriately selected premenopausal women and should be considered when non-pharmacological interventions have been insufficient" [9]. Virginia providers may reference ASRM guidance when documenting clinical rationale.

Comparing PT-141 to Other Sexual-Health Treatments Available in Virginia

| Treatment | FDA Approval | Controlled Substance | Mechanism | Virginia Legal Status | |---|---|---|---|---| | Bremelanotide (Vyleesi) | Yes (HSDD, premenopausal women) | No | Central MC4R agonist | Legal with Rx | | Flibanserin (Addyi) | Yes (HSDD, premenopausal women) | No | 5-HT1A agonist / 5-HT2A antagonist | Legal with Rx | | Sildenafil (Viagra) | Yes (male ED) | No | PDE5 inhibitor (peripheral) | Legal with Rx | | Tadalafil (Cialis) | Yes (male ED, BPH) | No | PDE5 inhibitor (peripheral) | Legal with Rx | | Oxytocin (intranasal, compounded) | No (compounded off-label) | No | Neuropeptide / social bonding | 503A Rx required |

The FDA approved flibanserin (Addyi) in August 2015 for the same indication as bremelanotide, but with an alcohol contraindication that limits its use. Providers in Virginia often choose between the two based on patient preference, alcohol use patterns, and tolerability profiles.